KWALITY PHARMACEUTICALS
|
KWALITY PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 64.90 | 38.40 | 22.93 | 18.67 | 115.64 |
| CEPS(Rs) | 84.00 | 55.99 | 41.61 | 33.00 | 125.89 |
| DPS(Rs) | - | - | - | - | - |
| Book NAV/Share(Rs) | 318.80 | 253.70 | 215.31 | 192.48 | 173.81 |
| Tax Rate(%) | 24.75 | 26.48 | 24.06 | 24.61 | 25.77 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 23.50 | 21.71 | 21.59 | 24.19 | 37.63 |
| EBIT Margin(%) | 19.97 | 17.29 | 13.51 | 12.82 | 36.06 |
| Pre Tax Margin(%) | 17.79 | 14.62 | 10.12 | 10.19 | 35.42 |
| PAT Margin (%) | 13.39 | 10.75 | 7.69 | 7.68 | 26.29 |
| Cash Profit Margin (%) | 17.32 | 15.69 | 14.06 | 13.64 | 28.64 |
| Performance Ratios | |||||
| ROA(%) | 13.01 | 9.48 | 6.32 | 5.55 | 47.33 |
| ROE(%) | 22.67 | 16.36 | 11.16 | 10.15 | 99.66 |
| ROCE(%) | 24.01 | 18.36 | 13.57 | 12.27 | 97.93 |
| Asset Turnover(x) | 0.97 | 0.88 | 0.82 | 0.72 | 1.80 |
| Sales/Fixed Asset(x) | 2.04 | 1.69 | 1.63 | 1.68 | 4.34 |
| Working Capital/Sales(x) | 2.79 | 3.24 | 3.38 | 3.09 | 5.16 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.49 | 0.59 | 0.61 | 0.59 | 0.23 |
| Receivable days | 157.57 | 132.46 | 110.56 | 102.38 | 41.94 |
| Inventory Days | 58.67 | 79.79 | 97.85 | 101.54 | 28.29 |
| Payable days | 160.16 | 157.23 | 161.90 | 183.20 | 78.14 |
| Valuation Parameters | |||||
| PER(x) | 20.13 | 22.63 | 17.85 | 16.47 | 5.02 |
| PCE(x) | 15.55 | 15.52 | 9.84 | 9.32 | 4.61 |
| Price/Book(x) | 4.10 | 3.43 | 1.90 | 1.60 | 3.34 |
| Yield(%) | - | - | - | - | - |
| EV/Net Sales(x) | 2.95 | 2.70 | 1.68 | 1.60 | 1.41 |
| EV/Core EBITDA(x) | 12.24 | 12.14 | 7.59 | 6.31 | 3.67 |
| EV/EBIT(x) | 14.76 | 15.61 | 12.46 | 12.49 | 3.91 |
| EV/CE(x) | 3.21 | 2.66 | 1.61 | 1.39 | 1.89 |
| M Cap / Sales | 2.69 | 2.44 | 1.38 | 1.27 | 1.32 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 35.90 | 20.52 | 22.36 | -44.97 | 74.11 |
| Core EBITDA Growth(%) | 47.13 | 20.79 | 7.03 | -63.65 | 475.48 |
| EBIT Growth(%) | 56.93 | 54.31 | 28.92 | -80.44 | 586.87 |
| PAT Growth(%) | 69.20 | 68.54 | 22.49 | -83.93 | 705.63 |
| EPS Growth(%) | 69.02 | 67.44 | 22.83 | -83.86 | 692.23 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.39 | 0.43 | 0.44 | 0.45 | 0.30 |
| Current Ratio(x) | 1.80 | 1.67 | 1.60 | 1.65 | 1.63 |
| Quick Ratio(x) | 1.45 | 1.18 | 1.08 | 0.96 | 1.25 |
| Interest Cover(x) | 9.16 | 6.48 | 3.99 | 4.87 | 56.38 |
| Total Debt/Mcap(x) | 0.10 | 0.12 | 0.23 | 0.28 | 0.09 |
Compare Financial Ratios of peers of KWALITY PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| KWALITY PHARMACEUTICALS | ₹3,456.9 Cr | -8.4% | 28.4% | 228.5% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,114.0 Cr | NA | -3.9% | 17.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹239,321.0 Cr | 5% | 21.5% | 44.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹185,924.0 Cr | -2.1% | -0.2% | 34.3% | Stock Analytics | |
| CIPLA | ₹113,778.0 Cr | -2% | -2.5% | -8.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,025.9 Cr | 0.4% | 4.5% | -4.4% | Stock Analytics | |
KWALITY PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| KWALITY PHARMACEUTICALS | -8.4% |
28.4% |
228.5% |
| SENSEX | 0.7% |
0.8% |
-5.1% |
You may also like the below Video Courses
